Macular Degeneration Treatment Market Size, Share & Trends Analysis Report By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration), By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD), By Route of Administration (Intravenous Route, Intravitreal Route), By Sales Channels (Ambulatory Surgical Centers, Hospitals, Other Sales Channels) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI2901DR

Author : Debashree Bora

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Macular Degeneration Treatment Market Size Analysis

Global Macular Degeneration Treatment Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Dry Age-related Macular Degeneration
  1. By Value
3. Wet Age-related Macular Degeneration
  1. By Value
By Stage of Disease
1. Introduction
  1. Stage of Disease By Value
2. Early-stage AMD
  1. By Value
3. Intermediate AMD
  1. By Value
4. Late-stage AMD
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Intravitreal Route
  1. By Value
By Sales Channels
1. Introduction
  1. Sales Channels By Value
2. Ambulatory Surgical Centers
  1. By Value
3. Hospitals
  1. By Value
4. Other Sales Channels
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Dry Age-related Macular Degeneration
  1. By Value
3. Wet Age-related Macular Degeneration
  1. By Value
By Stage of Disease
1. Introduction
  1. Stage of Disease By Value
2. Early-stage AMD
  1. By Value
3. Intermediate AMD
  1. By Value
4. Late-stage AMD
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Intravitreal Route
  1. By Value
By Sales Channels
1. Introduction
  1. Sales Channels By Value
2. Ambulatory Surgical Centers
  1. By Value
3. Hospitals
  1. By Value
4. Other Sales Channels
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-related Macular Degeneration
    1. By Value
  3. Wet Age-related Macular Degeneration
    1. By Value
2. By Stage of Disease
  1. Introduction
    1. Stage of Disease By Value
  2. Early-stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-stage AMD
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
4. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Dry Age-related Macular Degeneration
  1. By Value
3. Wet Age-related Macular Degeneration
  1. By Value
By Stage of Disease
1. Introduction
  1. Stage of Disease By Value
2. Early-stage AMD
  1. By Value
3. Intermediate AMD
  1. By Value
4. Late-stage AMD
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Intravitreal Route
  1. By Value
By Sales Channels
1. Introduction
  1. Sales Channels By Value
2. Ambulatory Surgical Centers
  1. By Value
3. Hospitals
  1. By Value
4. Other Sales Channels
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-related Macular Degeneration
    1. By Value
  3. Wet Age-related Macular Degeneration
    1. By Value
2. By Stage of Disease
  1. Introduction
    1. Stage of Disease By Value
  2. Early-stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-stage AMD
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
4. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Dry Age-related Macular Degeneration
  1. By Value
3. Wet Age-related Macular Degeneration
  1. By Value
By Stage of Disease
1. Introduction
  1. Stage of Disease By Value
2. Early-stage AMD
  1. By Value
3. Intermediate AMD
  1. By Value
4. Late-stage AMD
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Intravitreal Route
  1. By Value
By Sales Channels
1. Introduction
  1. Sales Channels By Value
2. Ambulatory Surgical Centers
  1. By Value
3. Hospitals
  1. By Value
4. Other Sales Channels
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-related Macular Degeneration
    1. By Value
  3. Wet Age-related Macular Degeneration
    1. By Value
2. By Stage of Disease
  1. Introduction
    1. Stage of Disease By Value
  2. Early-stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-stage AMD
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
4. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Dry Age-related Macular Degeneration
  1. By Value
3. Wet Age-related Macular Degeneration
  1. By Value
By Stage of Disease
1. Introduction
  1. Stage of Disease By Value
2. Early-stage AMD
  1. By Value
3. Intermediate AMD
  1. By Value
4. Late-stage AMD
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Intravitreal Route
  1. By Value
By Sales Channels
1. Introduction
  1. Sales Channels By Value
2. Ambulatory Surgical Centers
  1. By Value
3. Hospitals
  1. By Value
4. Other Sales Channels
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-related Macular Degeneration
    1. By Value
  3. Wet Age-related Macular Degeneration
    1. By Value
2. By Stage of Disease
  1. Introduction
    1. Stage of Disease By Value
  2. Early-stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-stage AMD
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
4. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Dry Age-related Macular Degeneration
  1. By Value
3. Wet Age-related Macular Degeneration
  1. By Value
By Stage of Disease
1. Introduction
  1. Stage of Disease By Value
2. Early-stage AMD
  1. By Value
3. Intermediate AMD
  1. By Value
4. Late-stage AMD
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous Route
  1. By Value
3. Intravitreal Route
  1. By Value
By Sales Channels
1. Introduction
  1. Sales Channels By Value
2. Ambulatory Surgical Centers
  1. By Value
3. Hospitals
  1. By Value
4. Other Sales Channels
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Dry Age-related Macular Degeneration
    1. By Value
  3. Wet Age-related Macular Degeneration
    1. By Value
2. By Stage of Disease
  1. Introduction
    1. Stage of Disease By Value
  2. Early-stage AMD
    1. By Value
  3. Intermediate AMD
    1. By Value
  4. Late-stage AMD
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous Route
    1. By Value
  3. Intravitreal Route
    1. By Value
4. By Sales Channels
  1. Introduction
    1. Sales Channels By Value
  2. Ambulatory Surgical Centers
    1. By Value
  3. Hospitals
    1. By Value
  4. Other Sales Channels
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Macular Degeneration Treatment Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Novartis AG
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Pfizer Inc.
Panoptica
Bausch Health Companies Inc.
Regeneron Pharmaceutical Inc.
Aerie Pharmaceutical Inc.
REGENXBIO Inc.
Bayer AG.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment

Appendix

Discussion Guide
Customization Options
Related Reports

Disclaimer

📊 Preview Report Scope and Structure – Gain immediate visibility into key topics, market segments, and data frameworks covered.
📥 Evaluate Strategic Insights – Access selected charts, statistics, and analyst-driven commentary derived from the final report deliverables.

Get Free Access

Table Of Content

We are featured on :

Sample Details